Increasing evidence shows that listening to music from childhood and early adulthood can help recall meaningful events from the past. Importantly, people with dementia have shown to benefit from listening to personally meaningful music, suggesting that musical memory remains preserved. However, the underlying mechanisms by which music improves memory remains unclear.
My research addresses the impact of an autobiographically salient music listening program on memory and brain activity in mild cognitive impairment. Understanding how brainwave activity in this population may differ, will help elucidate mechanisms of music listening that lead to cognitive improvements, ultimately providing insight into musical memory preservation and how it can be leveraged.
Participants will undergo cognitive testing and measure brainwave activity via EEG, a non-invasive neuroimaging method. Participants will be provided an online link (or CD if they do not have wifi) to access their personalized music playlist and will be asked to listen for two weeks at home (20 mins/day, minimum 5 days/wk). Repeated cognitive and EEG assessment will help determine changes in brain function.
- are 60 years of age and over
- have received a diagnosis of mild cognitive impairment; or are generally healthy
- are English speaking
- have a minimum of high school education
- have adequate hearing and vision
- can identify 15 English vocal/lyrical songs that are associated to your personal memories
- can commit to listening to your personal playlist (20 mins) at-home for 2 weeks (minimum 5 days/week)
The aim of our study is to better understand whether certain lifestyle factors (such as physical activity and hearing) are related to early changes in memory and thinking abilities in older adults. We are especially interested in enrolling individuals who are South Asian or East Asian, because little research has focused on brain health in Canadians of diverse racial/ethnic backgrounds.
By participating, you will help us better understand how lifestyle factors are related to memory and thinking changes in adults from diverse communities. We hope that this will lead to improved prevention and early intervention strategies for dementia.
You are eligible to participate if you…
- Are 55-85 years old
- Have no major medical or psychiatric diagnoses
- Are comfortable speaking and reading English
- Are able to undergo an MRI scan
Eligibility is dependent on an additional conversation with the study team.
[email protected] is a 5-week virtual reality at-home intervention with the goal to explore whether virtual reality experiences can enhance communication between persons living with dementia and their care partners. We also aim to explore how a head-mounted VR system, which delivers a fully immersive experience compares to a Tablet-based technology.
The study is aiming to assess whether nutritional intervention with personalized, preselected prebiotics can affect cognitive function in those with Alzheimer’s disease. This study is placebo-controlled, and participants will be randomized to either the placebo or prebiotic.
We want to determine if a nutrition questionnaire (SCREEN) works well to identify nutrition challenges for older adults with diagnosed memory problems, cognitive impairment or dementia when completed by themselves, or by a care partner on behalf of their cared for person.
You may be eligible if you are:
• 55 years or older
• Read/speak English
• Live within 45km of Waterloo, Guelph or London.
AND are an:
• Older adult with diagnosed memory problems, cognitive impairment or dementia with a care partner who either lives with you, or who is in daily contact with you and would be able to support reporting of their eating behaviours
• If living in a retirement home, the older adult must have lived in their home for at least 3 months and receive 2 or more meals each day from their retirement home
This is a randomized Phase IIa, multi-center, double-blind, placebo-controlled study of a new buccal film of montelukast in patients with mild to moderate Alzheimer's Disease.
50 years or older, with mild to moderate Alzheimer’s Disease
Participants will receive drug treatment via IV in clinic on Day 1 and every 4 weeks thereafter.
Multi-center, Double-Blind, Placebo-Controlled Phase 1/2 Trial to Assess the Safety and Tolerability of WVE-3972-01 Administered Intrathecally to Patients with Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD).
A Patient- and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Study Participants With Prodromal to Mild Alzheimer's Disease (AD), Followed by an Open-Label Extension Period.